Roche has purchased all shares of Austria-based mobile diabetes platform mySugr, strengthening its digital health services for diabetes care.
mySugr provides apps and services that combine diabetes coaching, therapy management, numerous test strips, automated data tracking, and integration with multiple medical devices.
The deal will integrate mySugr into the firm’s new patient-centred digital health services platform and is expected to boost Roche’s position in diabetes management.
Roche Diagnostics CEO Roland Diggelmann said: “We will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes.
“Having partnered with mySugr since 2014, we see an excellent cultural fit, as both our companies are passionate about taking diabetes management to the next level and making a difference in managing diabetes.”
mySugr will operate as a separate legal entity comprising an open platform for all diabetes devices and services, where users can automatically upload blood glucose data into the mySugr logbook app and share with healthcare professionals and caregivers.
mySugr CEO and co-founder Frank Westermann said: “We started mySugr to solve our everyday problems and simplify diabetes therapy through smartphones.
“The mySugr team has filled a gap for over a million loyal users so far, and with Roche’s diabetes expertise and global network, mySugr will become an indispensable companion for hassle-free life.”
Roche’s Diabetes Care unit provides diabetes management systems and services such as blood glucose monitoring systems.
The firm’s flagship Accu-Chek brand includes blood glucose metres, insulin delivery systems, lancing devices, data management systems and education programmes.
Image: Accu-Check insulin pump. Photo: courtesy of F Hoffmann-La Roche Ltd.